International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

Antibiotic Resistance and Pharmacovigilance Issues Related to Cefixime Use in India

Pranali Prakash Borse[1], Syeda Afifa[2]

[1]Student, Department of Pharmacy
[2]Assistant Professor, Department of Pharmacy
[1,2]Sayali Charitable Trust's College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India

Abstract:
Cefixime, an oral third-generation cephalosporin, is widely used in India for the management of respiratory, urinary, and enteric bacterial infections. Its extensive availability in both urban and rural markets, combined with frequent empirical prescribing, has resulted in increasing antimicrobial resistance across several pathogenic species. In recent years, resistance to Cefixime has emerged as a significant clinical and public-health concern, particularly among *Escherichia coli*, *Klebsiella pneumoniae*, *Neisseria gonorrhoeae*, and *Salmonella typhi*.
This review evaluates patterns of Cefixime resistance in India and explores contributing factors such as irrational antibiotic use, self-medication, over-the-counter accessibility, and inappropriate treatment durations. Additionally, the paper highlights pharmacovigilance gaps in monitoring adverse drug reactions and therapeutic failures, both of which are essential for detecting early resistance signals. Strengthening pharmacovigilance reporting, implementing antibiotic-stewardship programs, and promoting rational prescribing practices are critical steps for controlling the rise of Cefixime resistance in India.

Keywords: Cefixime, Antibiotic resistance, Pharmacovigilance, India, ADR monitoring, ESBL, AMR, Post-marketing surveillance.

1. Introduction

Antibiotic resistance has become one of the most critical public-health threats globally, with India being one of the major hotspots for antimicrobial misuse and rapidly evolving resistant pathogens. Among the commonly prescribed antibiotics, **Cefixime**, an oral third-generation cephalosporin, plays a significant role in the treatment of upper respiratory tract infections, urinary tract infections, otitis media, and enteric fever. Its broad-spectrum activity, favourable tolerability, and widespread availability have contributed to extensive use across government hospitals, private clinics, and community pharmacies in India [1], [2].
The high dependency on Cefixime in routine and empirical therapy has led to notable shifts in bacterial sensitivity patterns. Rising resistance has been documented in *Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella typhi*, and *Neisseria gonorrhoeae*, making its clinical effectiveness increasingly uncertain in several regions of India [3], [4]. Post-COVID-19 antibiotic overuse has further accelerated this trend, causing Cefixime to appear frequently in antimicrobial-resistance (AMR) surveillance reports issued by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC) [5].

Pharmacovigilance plays a crucial role in monitoring drug safety, including adverse drug reactions (ADRs) and therapeutic failures. In the context of antibiotics, therapeutic failure can be an early indicator of resistance and should therefore be incorporated into routine pharmacovigilance activities. However, in India, underreporting of ADRs, lack of awareness among healthcare professionals, and limited integration of resistance surveillance with pharmacovigilance databases continue to restrict early detection of Cefixime resistance signals [6], [7].

Thus, this review examines the emerging patterns of antibiotic resistance associated with Cefixime use in India and evaluates the pharmacovigilance challenges that hinder the identification and prevention of drug-related risks. It also highlights the need for improved antibiotic stewardship, rational prescribing, and strengthened national surveillance systems to mitigate the growing resistance burden.



2. Overview of Cefixime

Cefixime is an orally administered, third-generation cephalosporin antibiotic widely used in India for treating a broad range of bacterial infections. As a β-lactam antibiotic, it functions by inhibiting bacterial cell-wall synthesis through binding to penicillin-binding proteins (PBPs), ultimately leading to cell lysis and death [8]. Its enhanced stability against many β-lactamases, compared with earlier cephalosporins, initially made it a preferred choice for empirical therapy in both community and hospital settings.

Cefixime demonstrates good activity against several Gram-negative organisms, including *Escherichia coli*, *Proteus mirabilis*, *Haemophilus influenzae*, *Neisseria gonorrhoeae*, and *Salmonella* species, along with moderate activity against some Gram-positive bacteria [9], [10]. However, the growing emergence of extended-spectrum β-lactamase (ESBL)-producing bacteria and multidrug-resistant (MDR) strains has significantly limited its effectiveness. This decline in susceptibility has heightened concerns about its rational use and the need for enhanced surveillance.
Pharmacokinetically, Cefixime is characterized by moderate oral absorption, achieving a bioavailability of approximately 40–50%. Food may slightly delay absorption but does not reduce total bioavailability. It has an elimination half-life of 3–4 hours in adults and is excreted mainly unchanged via renal and biliary pathways [11]. Due to its convenient once- or twice-daily dosing schedule, it remains popular in both adult and paediatric therapy across India.
Clinically, Cefixime is approved for the treatment of upper respiratory tract infections, otitis media, uncomplicated urinary tract infections, typhoid fever, and uncomplicated gonorrhoea [12]. The Drug Controller General of India (DCGI) also recognizes its role in combination therapies for enteric fever and some community-acquired infections. Despite its wide clinical utility, inappropriate prescribing, empirical

use without culture confirmation, and over-the-counter accessibility have contributed to misuse, fuelling antimicrobial resistance across several Indian states [13], [14].
Overall, while Cefixime continues to be a commonly prescribed antibiotic in India, its declining sensitivity profile requires careful monitoring through antibiotic stewardship and pharmacovigilance programs.



3. Pattern of Cefixime Use in India

Cefixime has become one of the most widely prescribed oral antibiotics in India owing to its broad-spectrum activity, affordability, and availability across both urban and rural healthcare settings. Its use is particularly prominent in primary healthcare centers, private clinics, and community pharmacies where empirical therapy is commonly practiced [15]. As a result, the consumption of Cefixime has significantly increased over the last decade, often without adequate microbial testing or proper clinical justification.
A major contributor to its extensive use is the **over-the-counter (OTC) accessibility of antibiotics in India**, which allows patients to obtain Cefixime without a valid prescription. Multiple surveys conducted in northern and southern India have shown that community pharmacists frequently dispense Cefixime for symptoms like fever, sore throat, diarrhoea, and urinary discomfort—conditions that may have viral or non-bacterial etiologies [16], [17]. This practice accelerates unnecessary antibiotic exposure and increases the risk of resistance development.

Additionally, Cefixime is commonly included in **irrational fixed-dose combinations (FDCs)**, some of which lack robust clinical justification. These combinations often pair Cefixime with azithromycin, ofloxacin, or clavulanic acid, despite limited supportive evidence for enhanced efficacy in many routine infections [18]. Such combinations may promote inappropriate use and complicate resistance patterns due to simultaneous selective pressure on multiple antibiotic classes.
In paediatric populations, Cefixime is frequently prescribed for upper respiratory infections, even though most such infections are viral in origin. Studies have reported that up to 60% of paediatric prescriptions of Cefixime occur without culture-confirmed bacterial infection, highlighting the challenge of diagnostic uncertainty and the tendency to use broad-spectrum antibiotics as first-line agents [19].
Self-medication practices further contribute to the misuse of Cefixime. Patients often repeat previously prescribed antibiotic regimens without consulting a healthcare professional, leading to **underdosing, overdosing, and incomplete treatment durations** [20]. These patterns facilitate sub-therapeutic exposure, which is one of the strongest drivers of antimicrobial resistance.

Overall, the widespread, often irrational use of Cefixime in India has created an environment conducive to the rapid emergence and spread of resistant bacterial strains. Strengthening diagnostic stewardship, limiting OTC antibiotic sales, and enhancing prescriber awareness are essential steps toward rationalizing its use.



4. Antibiotic Resistance Trends of Cefixime in India

The rise of antimicrobial resistance (AMR) to Cefixime in India has become a major clinical and public-health challenge. Over the past decade, surveillance reports from the Indian Council of Medical Research (ICMR), National Centre for Disease Control (NCDC), and several tertiary-care hospitals have consistently shown increasing resistance among key Gram-negative pathogens [21]. This trend is primarily driven by uncontrolled antibiotic consumption, empirical prescribing, and high community-level demand for broad-spectrum oral antibiotics.

4.1 Resistance in Enterobacteriaceae

Among Enterobacteriaceae, **E. coli** and **Klebsiella pneumoniae** show some of the highest rates of Cefixime resistance. Multiple studies from North, South, and Western India have documented **resistance levels exceeding 60–70%** in urinary and bloodstream infections [22], [23]. The widespread presence of extended-spectrum β-lactamase (ESBL)-producing strains has significantly reduced the clinical utility of Cefixime in treating community-acquired UTIs.

ICMR-AMR data from 2022 and 2023 indicate a **steady upward trend** in resistance, especially in hospital settings where ESBL production is highly prevalent [24].

4.2 Resistance in *Salmonella typhi*

Cefixime was once a key oral option for treating typhoid fever in India; however, studies show a growing decline in susceptibility. Reports from Maharashtra, Delhi, and West Bengal reveal increasing minimum inhibitory concentrations (MICs), indicating early stages of treatment failure [25]. Although fully resistant strains remain uncommon, *reduced susceptibility* is an alarming development because it may compromise oral therapy options for typhoid, especially in areas with high fluoroquinolone resistance.

4.3 Resistance in *Neisseria gonorrhoeae*

Cefixime is a recommended treatment option for uncomplicated gonorrhoea, but resistance in *N. gonorrhoeae* has risen globally and is now emerging in India as well. Surveillance from the WHO-GASP network and Indian STI clinics has shown **decreased susceptibility and treatment failure** cases over the past 5–8 years [26], [27].



This raises concern about the future viability of Cefixime as part of gonorrhoea treatment guidelines.

4.4 Resistance in Respiratory Pathogens

In respiratory infections, increased resistance has been reported in *H. influenzae* and *S. pneumoniae*, although resistance levels vary across states. Regions with high unregulated antibiotic use—such as Uttar Pradesh, Bihar, Rajasthan, and Andhra Pradesh—show higher non-susceptibility rates [28].

4.5 Regional Variation in Resistance Rates

Resistance patterns show considerable geographical differences within India:

- **North India (Delhi, Haryana, Punjab):** High ESBL rates, reduced susceptibility to Cefixime in UTIs.
- **South India (Tamil Nadu, Karnataka):** Higher resistance in *Klebsiella* and post-COVID outpatient misuse.
- **East India (West Bengal, Odisha):** Increased *Salmonella* MICs.
- **West India (Maharashtra, Gujarat):** High resistance linked to self-medication and OTC availability [29].

These variations reflect differences in prescription habits, diagnostic access, and regulatory enforcement.

4.6 Therapeutic Failures

Several case studies from Indian tertiary-care hospitals report **clinical treatment failures** with Cefixime in UTIs, respiratory infections, and gonorrhoea [30]. Such therapeutic failures serve as early pharmacovigilance signals of emerging resistance and highlight the urgent need for integrated AMR-PV monitoring systems.

International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Overall, the increasing trend of Cefixime resistance threatens its continued utility in routine clinical practice. Strengthened surveillance, rational prescribing, and strict antibiotic stewardship are essential to limit further escalation.

5. Mechanisms of Cefixime Resistance

The development of resistance to Cefixime among bacterial pathogens in India is driven by several molecular and biochemical mechanisms. These resistance pathways significantly reduce the antibiotic's ability to bind to penicillin-binding proteins (PBPs) and inhibit cell-wall synthesis, ultimately leading to therapeutic failure. Understanding these mechanisms is essential for effective antibiotic stewardship and pharmacovigilance monitoring [31].

5.1 Extended-Spectrum β-Lactamases (ESBLs)

The most widespread mechanism of Cefixime resistance is the production of **extended-spectrum β-lactamases (ESBLs)**, especially among *E. coli* and *Klebsiella pneumoniae*. ESBL enzymes such as **CTX-M, SHV, and TEM variants** hydrolyze the β-lactam ring of Cefixime, rendering the antibiotic ineffective [32].

ESBL-producing organisms often carry resistance genes on plasmids, enabling rapid horizontal gene transfer among bacterial populations in hospitals and communities.



5.2 Alterations in Penicillin-Binding Proteins (PBPs)

Mutations or structural modifications in PBPs reduce Cefixime's binding affinity. This mechanism is especially relevant in **Neisseria gonorrhoeae**, where alterations in **PBP2** (encoded by the *penA* gene) significantly decrease susceptibility to Cefixime [33]. Mosaic *penA* alleles have been associated with high-level resistance and have been increasingly reported in South Asia.

5.3 Efflux Pump Overexpression

Many Gram-negative bacteria utilize **efflux pumps** such as **AcrAB-TolC** to actively expel Cefixime from the cell before it reaches effective intracellular concentrations [34]. Overexpression of these pumps leads to multidrug resistance (MDR), affecting not only Cefixime but several other antibiotic classes as well.

5.4 Reduced Permeability of Outer Membrane

Alterations in porin channels, particularly **OmpF and OmpC**, decrease Cefixime penetration into Gram-negative bacteria. Reduced permeability often occurs alongside ESBL production, compounding resistance levels [35].

5.5 β-Lactamase Hyperproduction

Some bacteria overproduce chromosomal β-lactamases such as **AmpC enzymes**, which confer resistance to many β-lactam antibiotics. Though Cefixime is more stable than earlier cephalosporins, high-level AmpC expression can still compromise its activity [36].

5.6 Mobile Genetic Elements and Horizontal Transmission

Plasmids, transposons, and integrons facilitate rapid spread of resistance genes across bacterial strains and species. This mechanism plays a major role in the regional clustering of Cefixime-resistant pathogens in India, where environmental, community, and hospital reservoirs enable constant gene transmission [37].

5.7 Biofilm Formation

Biofilms provide a protective environment that reduces antibiotic penetration and increases bacterial tolerance. Several pathogens, including *E. coli* and *Klebsiella*, form biofilms on urinary catheters and mucosal surfaces, reducing Cefixime's therapeutic efficacy [38].

Collectively, these mechanisms contribute to widespread Cefixime resistance and reinforce the need for continuous surveillance and pharmacovigilance to track emerging resistance determinants.

6. Mechanisms of Antibiotic Resistance Associated with Cefixime

Antibiotic resistance to third-generation cephalosporins such as **Cefixime** primarily arises due to bacterial genetic adaptation under antimicrobial pressure. These mechanisms reduce therapeutic effectiveness and contribute to treatment failures, especially in high-burden settings like India. Understanding these resistance pathways is essential for pharmacovigilance and early detection of emerging threats.

Cefixime exerts its pharmacological effect by binding to **penicillin-binding proteins (PBPs)** and inhibiting bacterial cell-wall synthesis. Resistance develops when bacteria modify the accessibility or affinity of these targets, degrade the drug, or expel it through efflux mechanisms. Most resistance mechanisms are well-documented in *Escherichia coli*, *Neisseria gonorrhoeae*, *Klebsiella pneumoniae*, and other Enterobacteriaceae frequently exposed to cephalosporins [21], [22].

6.1 β-Lactamase Production

The **most important resistance mechanism** against Cefixime is the production of **β-lactamases**, particularly:

- **Extended-Spectrum β-Lactamases (ESBLs)**
- **AmpC β-lactamases**
- **Carbapenemases** with cephalosporin activity

ESBL-producing *E. coli* and *Klebsiella* strains hydrolyze the β-lactam ring of Cefixime, rendering it largely ineffective [23]. These enzymes are usually plasmid-encoded, enabling rapid horizontal spread within hospital and community settings.

6.2 Target Modification (Altered PBPs)

Certain bacteria develop mutations in **penicillin-binding proteins**, reducing Cefixime's ability to bind effectively.

This is especially crucial in:

- **Neisseria gonorrhoeae** (PBP2 mutations decrease cefixime susceptibility)
- **Streptococcus pneumoniae** (mosaic PBPs)

Altered PBPs prevent Cefixime from inhibiting transpeptidation, allowing the bacteria to continue cell-wall synthesis despite antibiotic exposure [24], [25].

6.3 Reduced Membrane Permeability

Gram-negative bacteria may reduce cellular uptake of Cefixime by modifying their **outer membrane porins (OMPs)**.

Key features:

- Loss/mutation of **OmpF/OmpC** porins
- Decreased penetration of β-lactam antibiotics

- Synergistic effect with β-lactamase production

This mechanism is predominantly observed in ESBL-producing Enterobacteriaceae, especially in hospital isolates [26].



6.4 Efflux Pump Overexpression
Efflux systems such as:

- **AcrAB-TolC** (Enterobacteriaceae)
- **MtrCDE** (N. gonorrhoeae)

actively pump Cefixime molecules out of bacterial cells. When combined with porin loss or ESBL activity, efflux pumps dramatically increase MIC values and create multi-drug resistant (MDR) strains [27].
6.5 Biofilm-Mediated Resistance
Biofilms formed by *E. coli*, *Pseudomonas*, and other pathogens:

- Limit antibiotic penetration
- Promote quorum sensing
- Facilitate horizontal gene transfer

Within biofilms, Cefixime activity decreases as bacteria enter a metabolically inactive state, reducing drug susceptibility [28].
6.6 Plasmid-Mediated Resistance Spread in India
Carriage of resistance genes across India is mainly facilitated by:

- Conjugative plasmids (CTX-M, TEM, SHV genes)
- Transposons
- Integrons

These mobile genetic elements significantly accelerate the dissemination of ESBL-producing strains in community and hospital settings [29]. Surveillance studies show alarmingly high resistance rates in urinary tract infections, pediatric infections, and gonorrhea treatment cases [30].

7. Clinical Adverse Drug Reactions (ADRs) Associated With Cefixime

Cefixime is widely prescribed for respiratory infections, urinary tract infections, enteric fever, and sexually transmitted diseases in India. Although considered safer than many other cephalosporins, it is still associated with a spectrum of **dose-dependent and immune-mediated adverse drug reactions (ADRs)**. Monitoring these reactions is essential for pharmacovigilance systems because ADR patterns differ across regions due to antibiotic resistance, genetic factors, and prescribing practices [31], [32].

Cefixime-related ADRs are broadly categorized into:

1. **Gastrointestinal ADRs**,
2. **Hypersensitivity reactions**,
3. **Hematological abnormalities**,
4. **Hepatic effects**, and
5. **Rare but serious complications** such as *Clostridioides difficile* infection.



7.1 Gastrointestinal ADRs

GI effects are the most common reactions reported with Cefixime.

They occur in **5–15% of patients**, especially in pediatric populations and in those receiving prolonged therapy [33].

Common reactions include:

- **Diarrhea** (due to alteration of gut flora)
- **Abdominal pain**
- **Nausea and vomiting**
- **Dyspepsia**

Diarrhea is particularly significant because it may indicate **C. difficile–associated colitis**, a potentially life-threatening complication that must be monitored post-therapy [34].

7.2 Hypersensitivity Reactions

Cefixime, as a β-lactam antibiotic, may trigger immune-mediated hypersensitivity responses ranging from mild to severe.

Reported reactions include [35]:

- **Skin rash**
- **Urticaria**
- **Pruritus**
- **Drug fever**
- **Angioedema**
- **Anaphylaxis** (rare but serious)

Cross-reactivity can occur in individuals allergic to penicillin, though the rate is significantly lower compared to first-generation cephalosporins. Immediate discontinuation is recommended upon appearance of hypersensitivity symptoms.

7.3 Hematological Effects

Hematological toxicity with Cefixime is uncommon but clinically relevant.

Possible abnormalities include [36]:

- **Eosinophilia**
- **Leukopenia**
- **Thrombocytopenia**
- **Prolonged prothrombin time**

These effects are usually reversible after discontinuation. Patients on prolonged therapy or with hepatic/renal impairment should undergo periodic blood counts.

7.4 Hepatotoxicity

Mild elevations in hepatic enzymes such as **ALT**, **AST**, and **alkaline phosphatase** have been reported with Cefixime use [37].

Characteristics:

- Usually asymptomatic
- Reversible with cessation
- More common in elderly patients and those with comorbidities
- Rare cases of **cholestatic jaundice** documented

Regular hepatic monitoring may be beneficial in long-duration therapy.

7.5 Renal Adverse Effects

Although Cefixime is primarily excreted unchanged in urine, nephrotoxicity is rare.

Reported renal ADRs include [38]:

- **Mild increase in serum creatinine**
- **Interstitial nephritis** (immune-mediated; very rare)

Patients with pre-existing renal impairment require dose adjustments to prevent drug accumulation.

7.6 Neurological Effects

CNS adverse reactions are uncommon but may occur, especially in elderly patients or those with renal dysfunction (due to elevated serum levels).

Symptoms include [39]:

- Headache
- Dizziness
- Restlessness
- Insomnia
- Rare seizures (in overdose or renal failure)

7.7 Clostridioides difficile Infection (CDI)

Cefixime may predispose to CDI by disrupting intestinal flora and allowing *C. difficile* overgrowth [40].

Symptoms include:

- Severe watery diarrhea
- Abdominal tenderness
- Fever

International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

- Leukocytosis

This requires urgent medical intervention and is a critical safety signal for pharmacovigilance reporting.

7.8 ADR Patterns in Indian Population

Due to high antibiotic consumption and varying self-medication practices, India reports:

- Higher incidence of GI ADRs
- Increased allergic reactions in pediatric groups
- Higher CDI risk in hospitalized patients
- More severe ADRs in populations with polypharmacy

Studies emphasize the need for improved ADR monitoring and reporting systems in outpatient clinics and pharmacies [41].

8. Pharmacovigilance Systems and ADR Monitoring for Cefixime in India



Pharmacovigilance plays a central role in ensuring the safe and rational use of Cefixime across Indian healthcare systems. With rising antibiotic resistance, inappropriate self-medication, and the widespread use of Cefixime in both public and private sectors, strong surveillance networks are essential. The goal is to detect, assess, and prevent adverse drug reactions (ADRs), medication errors, and resistance-related treatment failures [42].

India's pharmacovigilance framework functions under **Pharmacovigilance Programme of India (PvPI)**, which is managed by the **Indian Pharmacopoeia Commission (IPC)**. Cefixime—being one of the most commonly prescribed oral third-generation cephalosporins—is subject to active monitoring, especially due to increasing reports of gastrointestinal ADRs, allergic reactions, and antimicrobial resistance patterns across the country.

8.1 Pharmacovigilance Programme of India (PvPI)

The PvPI was established to systematically collect and analyze ADR reports from healthcare institutions nationwide.

Key components relevant to Cefixime include [43]:

- **ADR Monitoring Centers (AMCs)** across government and private hospitals
- **Spontaneous reporting** by doctors, nurses, pharmacists, and consumers
- **Signal detection** for emerging reactions such as *C. difficile* infection or rising ESBL resistance
- **Integration with WHO-UMC global safety database (VigiBase)**
- **Feedback and regulatory recommendations**

PvPI plays a critical role in identifying new ADR trends for Cefixime, especially its misuse in URIs, UTIs, and typhoid fever.

8.2 ADR Reporting Methods for Cefixime

ADR reporting in India still faces challenges due to underreporting. For Cefixime, the following channels are commonly used [44]:

1. **Spontaneous ADR reporting form**
   - Filled by healthcare professionals or patients.
   - Submitted to the nearest AMC.
2. **PvPI Mobile App ("ADR PvPI")**
   - Allows quick reporting using smartphones.
   - Useful for pharmacists and rural practitioners.
3. **Toll-free PvPI helpline (1800-180-3024)**
   - For verbal ADR communication.
4. **Email and offline reporting** via hospital pharmacovigilance units.

Reporting involves documenting patient details, drug dose and duration, reaction onset, laboratory parameters, and dechallenge/rechallenge outcomes.

8.3 Signal Detection and Causality Assessment

After ADR submission, PvPI conducts **causality assessment** using methods such as:

- **WHO-UMC causality categories**
- **Naranjo ADR Probability Scale**

For Cefixime, signals often relate to:

- High rate of **diarrhea** and suspected CDI
- **Allergic skin reactions**
- **Renal impairment in elderly**
- **Possible treatment failure due to ESBL-producing organisms**

Signal detection enables early regulatory decisions, prescriber education, and antibiotic stewardship actions [45].

8.4 Role of Hospitals and Clinical Pharmacists

Hospital pharmacists and pharmacologists form the backbone of ADR surveillance.
Their key responsibilities include [46]:

- Actively monitoring patients receiving Cefixime
- Recording early warning signs (rash, diarrhea, hepatic enzyme elevation)
- Educating clinicians about resistance patterns
- Ensuring dosing adjustments for renal/hepatic impairment
- Preventing duplication or inappropriate prescription in outpatient settings

Many tertiary care hospitals have antibiotic stewardship committees that track Cefixime overuse, especially in pediatric wards and general medicine units.

8.5 Challenges in Cefixime Pharmacovigilance in India

Despite improvements, several challenges persist:

- **Underreporting** due to lack of awareness
- **High rate of over-the-counter antibiotic use**
- **Polypharmacy**, particularly among elderly patients
- **Limited microbiological testing** in rural hospitals
- **Delayed detection of ESBL outbreaks**
- **Poor documentation** in private clinics
- **Variation in quality of generic formulations**

These challenges compromise the accuracy of ADR signal detection and resistance mapping [47].

8.6 Strengthening Pharmacovigilance for Cefixime

Improvements needed include [48]:

- Public education on appropriate antibiotic use
- Mandatory ADR reporting training for healthcare workers
- Integration of pharmacies into PvPI reporting
- Real-time digital surveillance platforms
- Linking ADR reporting with antimicrobial stewardship programs
- Increasing microbiology lab capacity for resistance detection
- Feedback systems to prescribers regarding local resistance trends

Strengthened pharmacovigilance will eventually reduce preventable ADRs, resistance spread, and treatment failures associated with Cefixime.

9. Strategies to Combat Cefixime Resistance in India

The rising resistance to Cefixime in India necessitates a multipronged approach integrating **antimicrobial stewardship, pharmacovigilance, and public health interventions**. Effective strategies can limit the spread of resistant strains, reduce therapeutic failures, and ensure continued clinical utility of this antibiotic.

9.1 Rational Prescribing

Rational use of Cefixime is crucial to minimize resistance development [49]:

- Prescribing only for **confirmed bacterial infections**
- Avoiding empirical therapy for viral illnesses such as common cold
- Following **appropriate dose and duration guidelines**
- Avoiding fixed-dose combinations unless evidence supports efficacy
- Educating prescribers about local resistance patterns

Studies show that rational prescribing reduces selective pressure and preserves antibiotic effectiveness.

9.2 Antibiotic Stewardship Programs (ASP)

Hospital- and community-based **Antibiotic Stewardship Programs** (ASPs) play a key role in optimizing Cefixime use [50]:

- Regular review of prescriptions

- Restriction policies for broad-spectrum antibiotics
- Education of healthcare professionals on resistance trends
- Monitoring antibiotic consumption using defined daily doses (DDD)
- Integrating stewardship with pharmacovigilance systems

ASPs have proven effective in reducing inappropriate Cefixime use and improving clinical outcomes in India.

9.3 Public Education and Awareness

Self-medication and OTC use are major contributors to resistance [51]:

- Awareness campaigns for **patients and caregivers**
- Highlighting risks of incomplete courses and unsupervised antibiotic use
- Promoting **consultation with licensed physicians** before taking antibiotics
- Disseminating information through digital media, community health workers, and pharmacies

Such interventions help curb misuse in both urban and rural populations.

9.4 Strengthening Pharmacovigilance and ADR Reporting

Enhanced pharmacovigilance ensures early detection of ADRs and resistance signals [52]:

- Encouraging **active and spontaneous ADR reporting** for Cefixime
- Integrating **resistance surveillance with pharmacovigilance**
- Using real-time digital tools for signal detection
- Providing feedback to clinicians regarding **emerging resistance patterns**

This approach allows rapid identification of treatment failures and informs policy decisions.

9.5 Microbiological Surveillance

Routine **culture and sensitivity testing** should guide Cefixime therapy [53]:

- Hospitals and diagnostic centers should **report susceptibility patterns**
- National and regional AMR databases must be updated regularly
- Encourage **targeted therapy based on pathogen-specific MICs**
- Detecting ESBL and AmpC producers early to avoid ineffective therapy

Such practices reduce empirical use and help in tailoring therapy appropriately.

9.6 Regulatory Measures

Government and regulatory agencies must enforce guidelines to control resistance [54]:

- Restrict **OTC sales of antibiotics**
- Monitor **quality of generic Cefixime formulations**
- Implement **policies for rational FDC use**
- Support **nationwide AMR surveillance**
- Incentivize hospitals to report ADRs and resistance trends

These steps reinforce national antibiotic stewardship strategies.

9.7 Research and Development

Continuous research is critical for understanding Cefixime resistance and developing alternatives [55]:

- Investigating **new β-lactamase inhibitors**
- Developing **adjunct therapies** to enhance Cefixime activity
- Exploring **pharmacokinetic/pharmacodynamic optimization**
- Studying **genomic determinants of resistance** to predict outbreaks

R&D strengthens the evidence base for safe and effective Cefixime use.

10. Future Directions and Research Opportunities

Addressing Cefixime resistance and optimizing its safe use in India require forward-looking strategies. Future efforts should focus on enhancing **pharmacovigilance, improving antibiotic stewardship, and advancing scientific research** to preserve the therapeutic efficacy of Cefixime while minimizing adverse events.

10.1 Integration of Pharmacovigilance and Antimicrobial Resistance Surveillance

Currently, ADR monitoring and AMR surveillance often function independently. Integrating these systems will allow **real-time tracking of treatment failures and emerging resistance** [56]. Digital platforms linking hospitals, laboratories, and regulatory bodies can facilitate:

- Early detection of ADR clusters
- Identification of high-resistance regions
- Prompt feedback to prescribers on local susceptibility patterns

Such integration supports data-driven decision-making and reduces inappropriate Cefixime use.

10.2 Personalized Antibiotic Therapy

Pharmacogenomics and precision medicine can guide **patient-specific Cefixime therapy** [57]:

- Dose adjustments based on renal/hepatic function
- Avoiding hypersensitivity in genetically predisposed individuals
- Tailoring therapy according to microbiome composition

Personalized therapy may reduce ADR incidence and improve treatment success.

10.3 Development of Novel Adjuncts and Formulations

Research should focus on enhancing Cefixime efficacy and reducing resistance [58]:

- **Combination therapies with β-lactamase inhibitors**
- **Extended-release or targeted-delivery formulations**
- **Nanoformulations** to improve bioavailability and tissue penetration

These approaches may help restore clinical utility in resistant infections.

10.4 Strengthening Community and Rural Health Education

Effective public health interventions remain crucial [59]:

- Education on proper antibiotic use
- Awareness of treatment adherence and completion
- Discouraging self-medication and OTC misuse

Community-based programs can significantly reduce the selective pressure driving resistance.

10.5 Encouraging Multicenter Clinical Studies

Large-scale observational studies and randomized controlled trials are needed to:

- Quantify the **real-world incidence of ADRs** for Cefixime
- Track **treatment outcomes across diverse Indian populations**

- Understand **geographic variations in resistance patterns**
- Evaluate **the effectiveness of stewardship interventions** [60]

Such evidence will inform national guidelines and regulatory policies.

10.6 Policy and Regulatory Research

Future research must also explore **policy-level interventions**:

- Optimizing **OTC sale regulations**
- Developing **standardized antibiotic prescription protocols**
- Assessing the **impact of stewardship programs on resistance trends**
- Encouraging **industry partnerships for safer generic formulations** [61]

These initiatives will ensure sustainable antibiotic use and reduce the public health burden of resistant infections.

11. Conclusion

Cefixime remains a widely prescribed third-generation cephalosporin in India due to its broad-spectrum activity and oral bioavailability. However, widespread empirical use, over-the-counter availability, and incomplete adherence have contributed to **rising antimicrobial resistance** and an increasing incidence of adverse drug reactions. The prevalence of ESBL-producing *E. coli*, altered PBPs in *Neisseria gonorrhoeae*, and multidrug-resistant Enterobacteriaceae underscore the urgent need for **robust pharmacovigilance, rational prescribing, and antimicrobial stewardship programs**.

Pharmacovigilance plays a crucial role in identifying ADRs, monitoring resistance trends, and providing actionable feedback to prescribers and policymakers. Strengthening ADR reporting systems, integrating resistance surveillance with pharmacovigilance, promoting public awareness, and conducting multicenter clinical studies are essential steps to preserve Cefixime's therapeutic effectiveness.

Future strategies should emphasize **personalized antibiotic therapy, development of novel drug formulations, targeted public education, and policy-level interventions**. A coordinated approach involving healthcare professionals, regulatory authorities, and the public can significantly reduce the emergence and spread of resistant pathogens, improve patient safety, and ensure sustainable use of Cefixime in India.

In conclusion, **Cefixime use in India highlights the intersection of clinical practice, antimicrobial resistance, and pharmacovigilance**, emphasizing the importance of evidence-based interventions to safeguard public health.

REFERENCES:

1. J. Barré, "Pharmacokinetic properties of cefixime," *Presse Méd.*, vol. 18, no. 32, pp. 1578–1582, Oct. 1989.
2. G. Montay et al., "Pharmacokinetics of cefixime in healthy volunteers after a single oral dose," *J. Antimicrob. Chemother.*, 1989.
3. R. N. Brogden, "Cefixime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use," *Drugs*, vol. 37, no. 3, pp. 375–398, 1989.
4. S. Mermer, D. Akyol, M. B. Özkara, S. Şöhret Aydemir, O. R. Sipahi, "Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: in vitro synergy and clinical outcomes," *BMC Infect. Dis.*, vol. 25, 2025.
5. B. Kar, A. Barik, and S. Biswal, "Prevalence and molecular characterization of β-lactamase–producing Enterobacteriaceae in Northeast India," *Microb. Pathog.*, 2021.
6. V. L. Handa, B. N. Patel, A. Bhattacharya, and R. K. Kothari, "A study of antibiotic resistance pattern of clinical bacterial pathogens isolated from patients in a tertiary care hospital," *Front. Microbiol.*, 2024.
7. V. Kumar and S. Sharma, "Cefixime-associated acute generalized exanthematous pustulosis (AGEP): a case report," *Int. J. Dermatol.*, 2018.

8. V. A. Deva Rao, I. Khan, and S. Velupula, "A case series of cefixime-induced Stevens-Johnson Syndrome," *Int. J. Basic Clin. Pharmacol.*, vol. 7, no. 8, pp. 1648–1651, 2018.
9. "Cefixime (oral route) — Side effects & dosage," *Mayo Clinic*, 31 Jul. 2025.
10. "Cefixime — MedlinePlus Drug Information," *MedlinePlus*, 15 Jan. 2022.
11. I. F. Mitropoulos and J. M. Quartarolo, "Adverse events associated with the use of oral cephalosporins in children," *Pediatr. Infect. Dis. J.*, vol. 26, no. 2, 2007.
12. "Cefixime: Uses, Interactions, Mechanism of Action," *DrugBank*, 2025.
13. A. Wiesner et al., "Pharmacokinetic parameters of extended-half-life β-lactam antibiotics (including cefixime)," *J. Antimicrob. Chemother.*, vol. 79, no. 4, pp. 722–731, 2024.
14. T. Singhal, "Antimicrobial resistance: The 'Other' Pandemic!," *Indian Pediatr.*, vol. 59, no. 9, pp. 727–732, 2022.
15. S. Chandra, A. Thomas, and S. Mehta, "Antimicrobial resistance: Call for rational antibiotics practice in India," *J. Fam. Med. Prim. Care*, vol. 9, no. 2, pp. 460–466, 2020.
16. Department of Biotechnology, Government of India, "Scoping Report on Antimicrobial Resistance in India," 2017.
17. Indian Pharmacopoeia Commission, "Pharmacovigilance Programme of India (PvPI) – About."
18. Indian Pharmacopoeia Commission, "PvPI – ADR Reporting."
19. IPC, "PvPI-Frequently Asked Questions."
20. IPC, "ADR Reporting Form (regional languages)."
21. S. Mermer, D. Akyol, M. B. Özkara, S. Şöhret Aydemir, O. R. Sipahi, "Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series," *BMC Infect. Dis.*, 2025.
22. J. Ayatollahi and S. J. Gonchelar, "Antibiotic Resistance Patterns of *Escherichia coli* Isolated from Urine Samples," *J. Clin. Diagn. Res.*, 2013.
23. F. Shao, "Beta-Lactamase-Mediated Antibiotic Resistance in Urinary Tract Infection: Role of Cefixime and Clavulanate," *UTI Journal*, 2025.
24. S. Goudar et al., "Strategies and Recent Advances in Tackling Antibacterial-Resistance in India: A Comprehensive Narrative Review," *Cureus*, 2025.
25. M. Al-Tamimi et al., "Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum β-lactamases in E. coli," *J. Clin. Microbiol.*, 2022.
26. D. Ramdhani, "Comparative study of cefixime and tetracycline as an antibiotic for acute respiratory infection," *Scientific Reports*, 2021.
27. A. Chakrabarti et al., "NAMS Task Force Report on Antimicrobial Resistance," *National AMS-India Report*, 2024.
28. J. Kaur et al., "Emerging trends in antimicrobial resistance in bloodstream infections across India," *Lancet Regional Health – Southeast Asia*, 2024.
29. S. Sood et al., "Analysis of Neisseria gonorrhoeae susceptibility trends and MIC creep from North India: A 15-year experience," *Indian J. Dermatol. Venereol. Leprol.*, 2025.
30. D. Ramdhani et al., "Comparative study of cefixime and tetracycline as an antibiotic for acute respiratory infection," *Scientific Reports*, 2021.
31. N. Livermore, "Oxyimino-cephalosporin–clavulanate combinations against ESBL-producing bacteria," *J. Antimicrob. Chemother.*, 2008.
32. Impact of Antibiotic Stewardship Programs in Indian Hospitals, "Evaluation of the Impact of ASPs on Cephalosporin and Carbapenem Resistance," *IJCPR*, 2025.
33. A. Khan, "Fighting antimicrobial resistance in India: Role of policy and stewardship," *NJPPP Journal*, 2023.
34. WHO, "Multi-drug resistant gonorrhoea fact sheet," 2025.
35. T. Goudar et al., "Strategies and Recent Advances in Tackling Antibacterial-Resistance in India: A Comprehensive Narrative Review," *Cureus*, 2025.

36. S. Sawant, “Knowledge, attitudes and practices related to the use of oral antibiotics in community-acquired pneumonia in India,” *AJMS*, 2025.
37. V. P. Singh, “A mini-review on the burden of antimicrobial resistance in India,” *Science Direct Reviews*, 2024.
38. K. N. Chakrabarti et al., “NAMS Task Force Report on Antimicrobial Resistance,” 2024.
39. SEFI Network, “Recent emergence of cephalosporin-resistant Salmonella Typhi in India due to plasmid-mediated ESBL genes,” *PMC*, 2024.
40. Clinical Effectiveness and Safety of Cefixime in Indian Typhoid Patients, *Annals of Medicine & Medical Sciences*, 2025.
41. “Regional variations in antimicrobial susceptibility of uropathogenic E. coli in India,” multicentric study, *PMC*, 2023.
42. IPC, “Pharmacovigilance Programme of India (PvPI) Toolkit.”
43. IPC, “Monthly Drug Safety Alert – Fixed Drug Eruption Cephalosporins (including cefixime),” PvPI, 2022.
44. S. Chandra, A. Thomas, and S. Mehta, “Antimicrobial resistance: Call for rational antibiotics practice in India,” *J. Fam. Med. Prim. Care*, vol. 9, no. 2, pp. 460–466, 2020.
45. T. Singhal, “Antimicrobial resistance: The ‘Other’ Pandemic!,” *Indian Pediatr.*, vol. 59, no. 9, pp. 727–732, 2022.
46. V. L. Handa, B. N. Patel, A. Bhattacharya, and R. K. Kothari, “A study of antibiotic resistance pattern of clinical bacterial pathogens isolated from patients in a tertiary care hospital,” *Front. Microbiol.*, 2024.
47. B. Kar, A. Barik, and S. Biswal, “Prevalence and molecular characterization of β-lactamase–producing Enterobacteriaceae in Northeast India,” *Microb. Pathog.*, 2021.
48. S. Mermer, D. Akyol, M. B. Özkara, S. Şöhret Aydemir, O. R. Sipahi, “Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: in vitro synergy and clinical outcomes,” *BMC Infect. Dis.*, 2025.
49. R. N. Brogden, “Cefixime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use,” *Drugs*, vol. 37, no. 3, pp. 375–398, 1989.
50. J. Barré, “Pharmacokinetic properties of cefixime,” *Presse Méd.*, vol. 18, no. 32, pp. 1578–1582, Oct. 1989.
51. V. Kumar and S. Sharma, “Cefixime-associated acute generalized exanthematous pustulosis (AGEP): a case report,” *Int. J. Dermatol.*, 2018.
52. V. A. Deva Rao, I. Khan, and S. Velupula, “A case series of cefixime-induced Stevens-Johnson Syndrome,” *Int. J. Basic Clin. Pharmacol.*, vol. 7, no. 8, pp. 1648–1651, 2018.
53. I. F. Mitropoulos and J. M. Quartarolo, “Adverse events associated with the use of oral cephalosporins in children,” *Pediatr. Infect. Dis. J.*, vol. 26, no. 2, 2007.
54. A. Wiesner et al., “Pharmacokinetic parameters of extended-half-life β-lactam antibiotics (including cefixime),” *J. Antimicrob. Chemother.*, vol. 79, no. 4, pp. 722–731, 2024.
55. T. Singhal, “Antimicrobial resistance: The ‘Other’ Pandemic!,” *Indian Pediatr.*, vol. 59, no. 9, pp. 727–732, 2022.
56. S. Chandra, A. Thomas, and S. Mehta, “Antimicrobial resistance: Call for rational antibiotics practice in India,” *J. Fam. Med. Prim. Care*, vol. 9, no. 2, pp. 460–466, 2020.
57. Department of Biotechnology, Government of India, “Scoping Report on Antimicrobial Resistance in India,” 2017.
58. WHO, “Multi-drug resistant gonorrhoea fact sheet,” 2025.
59. Indian Pharmacopoeia Commission, “PvPI – ADR Reporting.”
60. IPC, “PvPI-Frequently Asked Questions.”
61. IPC, “ADR Reporting Form (regional languages).”